Clinical trials: Mitral Heart Valve Disease
Mitral Valve Insufficiency, Coronary Artery Disease
Long Term Follow Up for CTSN Mitral Valve Repair Studies
This study is a continuation of two previous studies --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- to learn more about…
- Trial name
- NCT03066050
- Testing
- MV Repair, MV Replacement, CABG
- Where
- 24 sites in United States, Canada
- Volunteers
- 368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Mitral Valve Prolapse, Mitral Regurgitation
Patient Specific Mitral Valve Modeling for Surgical Planning and Training
Mitral valve disease is a common pathologic problem occurring in approximately 2% of the general population but climbing to 10% in those over the age of 75 in Canada[1].
- Conditions
- Mitral Valve Prolapse, Mitral Regurgitation, Mitral Valve Disease
- Trial name
- NCT03609931
- Testing
- Mitral Valve Model
- Volunteers
- 65 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mitral Regurgitation (MR)
The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair
A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER
- Trial name
- SK M-CLIP (NCT07045753)
- Testing
- Transcatheter edge to edge repair
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Segeberger Kliniken GmbH
Hypertrophic Obstructive Cardiomyopathy
Mitral Valve in Hypertrophic Cardiomyopathy
The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve…
- Trial name
- NCT03877731
- Testing
- isolated septal myectomy, septal myectomy + edge-to-edge mitral valve repair, septal myectomy + posterior leaflet sliding plasty
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Residual Mitral Regurgitation
Multiparametric Protocol for Assessment of Intraprocedural Result of MITRACLIP Procedure
Quantification of residual mitral regurgitation (MR) after MitraClip may be challenging. Quantitative methods for severity assessment may be inaccurate and recent recommendations suggest an assessment of changes in both…
- Trial name
- IPCLIP-2020 (NCT06184789)
- Testing
- Echocardiographic assessment
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS San Raffaele
Mitral Valve Regurgitation (Degenerative or Functional)
TVMR With the Innovalve System Trial - Pilot in Georgia
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
- Trial name
- TWIST-PILOT-GE (NCT05682066)
- Testing
- Innovalve MR system
- Where
- Georgia
- Volunteers
- 11 people
- Sponsor
- Edwards Lifesciences
Mitral Regurgitation Functional
Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation
Implantation of the MitraClip has become the most frequently used percutaneous technique to treat significant (grade 3+ or 4+) mitral regurgitation (MR) in elderly patients deemed inoperable or at high surgical risk.
- Trial name
- One-Plus-One (NCT03503851)
- Testing
- MitraClip implantation
- Sponsor
- Asklepios proresearch
Mitral Regurgitation
The Effect of Percutaneous Superior Venae Cava Cannulation Clamping on Cerebral Near Infrared Spectroscopy in MICS
The use of minimally invasive cardiac surgery has progressed over the last 5-10 years to allow access to the heart through a small incision in the right chest.
- Trial name
- NIRSinMICS (NCT01166841)
- Testing
- PSVC line clamped
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mitral Valve Regurgitation, Mitral Valve Prolapse
CE Mark Study for the Harpoon Medical Device
The purpose of this study is to evaluate the safety and performance of the Harpoon Medical device. It is anticipated, that the Harpoon Medical device will provide advantages over current surgical interventions including: 1) a…
- Conditions
- Mitral Valve Regurgitation, Mitral Valve Prolapse, Mitral Valve Insufficiency
- Trial name
- TRACER (NCT02768870)
- Testing
- Harpoon Artificial ePTFE Chords
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Edwards Lifesciences
Mitral Valve Insufficiency, Left Ventricular Dysfunction
Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
Functional MR is caused by adverse left ventricular remodeling after myocardial injury and associated with an increased incidence of heart failure and death.
- Trial name
- PRIME (NCT02687932)
- Testing
- LCZ696, Valsartan
- Where
- 4 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Asan Medical Center
Mitral Regurgitation
Beating Heart Mitral Valve Repair With the HARPOON™ System
The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).
- Trial name
- RESTORE (NCT04375332)
- Testing
- HARPOON™ Beating Heart Mitral Valve Repair System
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Edwards Lifesciences
Mitral Regurgitation, Tricuspid Regurgitation
Early Discharge After Mitral and Tricuspid Edge-to-edge Repair: an Assessment of Feasibility and Safety
Mitral regurgitation (MR) and tricuspid regurgitation (TR) are common causes of breathlessness, fluid retention and other heart failure symptoms, which lead to reduced quality of life and frequent hospitalisation.
- Conditions
- Mitral Regurgitation, Tricuspid Regurgitation, Mitral Repair, Heart Failure
- Trial name
- EARLY-Edge (NCT06343363)
- Testing
- Early discharge protocol
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Oxford University Hospitals NHS Trust
Myocardial Ischemia, Coronary Arteriosclerosis
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo…
- Conditions
- Myocardial Ischemia, Coronary Arteriosclerosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency
- Trial name
- NCT00082121
- Testing
- TP10
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Avant Immunotherapeutics
Mitral Regurgitation
Tendyne European Experience Registry
TENDER is a multicenter, single-device, retrospective and prospective, observational study to assess safety and efficacy of the Tendyne Mitral Valve System in a real-world population.
- Trial name
- TENDER (NCT04898335)
- Testing
- Tendyne Mitral Valve System
- Where
- 30 sites in Austria, Belgium and 8 more
- Volunteers
- 400 people
- Sponsor
- LMU Klinikum
Mitral Valve Insufficiency, Aortic Stenosis Senile
Clinical and Geriatric Assessment in Elderly Patients Before and After TAVI or MitraClip Positioning
Since October of 2014, the Policlinico Umberto I Hospital has an "Heart Team", a group of selected specialists with the task of assessing and identifying eligible patients for valvular aortic transcatheter implantation (TAVI) or…
- Trial name
- NCT03145376
- Testing
- geriatric assessment
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Aortic Stenosis, Mitral Regurgitation
Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.
To evaluate whether patients after successful transfemoral transcatheter aortic valve implantation (TAVI), who have concomitant, moderate to severe mitral regurgitation (MR) benefit from an additional treatment of this valve…
- Trial name
- MITAVI (NCT04009434)
- Testing
- Mitral Valve Clipping, TAVI
- Where
- Germany
- Volunteers
- 1,162 people
- Sponsor
- Technische Universität Dresden
Rheumatic Heart Disease, Acute Rheumatic Fever
Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren
Rheumatic heart disease remains a major challenge in low and middle income countries. Early detection of clinically silent valvular lesions by screening echocardiography allows timely implementation of secondary antibiotic…
- Trial name
- NCT02353663
- Testing
- Echocardiography
- Where
- 2 sites in Peru, Switzerland
- Volunteers
- 1,023 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Mitral Regurgitation, Mitral Valve Disease
Caisson Transcatheter Mitral Valve Replacement (TMVR)
The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).
- Conditions
- Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Failure, Mitral Disease
- Trial name
- INTERLUDE (NCT03661398)
- Testing
- Transcatheter Mitral Valve Replacement
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Caisson Interventional LLC
Mitral Regurgitation
Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure in the volume overload of mitral…
- Trial name
- P1A1 (NCT01052428)
- Testing
- metoprolol succinate (Toprol XL)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Mitral Valve Regurgitation (Degenerative or Functional)
TVMR With the Innovalve System Trial - TWIST-BE TWIST-PILOT-BE
Study to evaluate the safety and performance of the Innovalve mitral valve replacement system
- Trial name
- NCT05263375
- Testing
- Innovalve TMVR system
- Sponsor
- Innovalve Bio Medical Ltd.